Stocktoria
NEOGENOMICS INC NEO
Nasdaq · XNAS · stock · Services-Testing Laboratories · website · IPO 2012-12-10
NEOGENOMICS INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $727.3M | $660.6M | $591.6M | $509.7M | $484.3M |
| Gross profit | $314.3M | $290.1M | $244.6M | $187.9M | $187.1M |
| R&D expense | $37.1M | $31.2M | $27.3M | $30.3M | $21.9M |
| Operating income | -$115.9M | -$92.1M | -$107.7M | -$157.6M | -$118.8M |
| Interest expense | — | — | $6.9M | $7.6M | $8.2M |
| Income tax | -$2.2M | -$1.9M | -$9.1M | -$15.1M | -$6.7M |
| Net income | -$108.0M | -$78.7M | -$88.0M | -$144.2M | -$8.3M |
| Operating cash flow | $5.2M | $7.0M | -$2.0M | -$66.0M | -$26.7M |
| Free cash flow | -$21.8M | -$34.0M | -$30.7M | -$96.9M | -$90.9M |
| Cash & equivalents | $159.6M | $367.0M | $342.5M | $263.2M | $316.8M |
| Inventory | $28.6M | $26.7M | $24.2M | $24.3M | $23.4M |
| Total assets | $1.4B | $1.6B | $1.7B | $1.7B | $1.9B |
| Total liabilities | $523.3M | $735.7M | $739.7M | $742.0M | $761.5M |
| Shareholders' equity | $836.6M | $902.3M | $941.5M | $998.0M | $1.1B |
Source: SEC EDGAR filings · CIK 0001077183 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.